Skip to search formSkip to main contentSkip to account menu

esketamine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The substantive delay (often 4–6 weeks) between the commencement of an antidepressant and any discernible improvement in… 
2020
2020
Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in… 
Review
2020
Review
2020
Since the FDA approved intranasal esketamine, there has understandably been significant dialogue, debate, and discussion about… 
2019
2019
An advisory committee to the US Food and Drug Administration (FDA) has strongly endorsed esketamine, a derivative of the… 
Review
2016
Review
2016
Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal… 
2016
2016
Clinical trial failures of two drugs for hearing loss and tinnitus underscore pitfalls for a nascent area of drug development… 
2016
2016
Pivotal trials of Alkermes's antidepressant ALKS 5461 show how a patented clinical trial design might be able to help control… 
Review
2016
Review
2016
OBJECTIVE The pathogenesis and etiology of still remain unknown. Current evidence suggests that the occurrence of depression may… 
2003
2003
OBJECTIVES The study was undertaken to compare different anaesthetic techniques for scheduled or urgent caesarean section with…